[Differentiation of neuroleptic and psychosedative effects in screening].
D000818:Animals; D002707:Chlordiazepoxide / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003864:Depression, Chemical; D003975:Diazepam / Q000494:pharmacology; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008297:Male; D008620:Meprobamate / Q000494:pharmacology; D008694:Methamphetamine; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D010634:Phenobarbital / Q000494:pharmacology; D013268:Stimulation, Chemical; D014149:Tranquilizing Agents / Q000494:pharmacology*
D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents; D008694:Methamphetamine; D002707:Chlordiazepoxide; D008620:Meprobamate; D003975:Diazepam; D002746:Chlorpromazine; D010634:Phenobarbital
Eine Möglichkeit zur Differenzierung neuroleptischer und psychosedativer Wirkungen im Screening.